Noemı́ Reguart

Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer

Manon A. Simard, Elba Marín, Silvia García-Román, Cristina Aguado et autres

AIM: Type Ib MET inhibitors are clinically active in selected MET-altered non-small cell lung cancer, particularly tumors with MET exon 14 skipping or MET amplification, but acquired resistance remains incompletely understood. Here, we investigated resistance across biologically distinct MET-altered contexts, including MET …

de, es, us (code pays fourni par la source)

Osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD

Jonathan Wade Goldman, Jonathan W. Riess, Byoung Chul Cho, Sarah B. Goldberg et autres

Background ORCHARD (NCT03944772) was a biomarker-directed, phase II, platform study conducted to characterise resistance mechanisms and evaluate novel treatment combinations in patients with epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC) following progression on first-line osimertinib. We report …

us, kr, jp, es, se, nl, no, sg (code pays fourni par la source)

Data from First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study

Jhanelle E. Gray, Joel W. Neal, Jyoti D. Patel, Stephen V. Liu et autres

AbstractPurpose: EVOKE-02 (NCT05186974) is a multicohort, phase II trial evaluating first-line sacituzumab govitecan (SG) plus pembrolizumab with or without platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (mNSCLC). Patients and Methods: Adults with mNSCLC, no prior systemic treatment, and no …

Supplementary Data 1 from First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study

Jhanelle E. Gray, Joel W. Neal, Jyoti D. Patel, Stephen V. Liu et autres

Supplementary Data

Figure S9 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Supplementary Figure 9. Deconvolution scores differ by pathological response in the areas of interest.

Figure S1 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Supplementary Figure 1. Tumor BCR repertoire dynamics, correlations and potential as biomarker.

Figure S4 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Supplementary Figure 4. Normalized expression of B cell related ChIO-induced genes.

Figure S6 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Supplementary Figure 6. B-cell regions analyzed by Visium spatial transcriptomics.

Table S8 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Visium DEG per main phenotype by response

Table S11 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Phenotype-location correlations by response

Figure S8 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Supplementary Figure 8. Deconvolution scores reflect spatial tissue architecture.

Figure S2 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer

Belén Sierra‐Rodero, Ángeles Gil-González, Marta Molina-Alejandre, Ernest Nadal et autres

Supplementary Figure 2. BCR repertoire dynamics.